Novel effects of hormonal contraceptive use on the plasma proteome.

Hormonal contraceptive (HC) use may increase cardiometabolic risk; however, the effect of HC on emerging cardiometabolic and other disease risk factors is not clear.To determine the association between HC use and plasma proteins involved in established and emerging disease risk pathways.Concentratio...

Full description

Bibliographic Details
Main Authors: Andrea R Josse, Bibiana Garcia-Bailo, Karina Fischer, Ahmed El-Sohemy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3440362?pdf=render
id doaj-07e10c78a0694191befecc60709955aa
record_format Article
spelling doaj-07e10c78a0694191befecc60709955aa2020-11-25T02:39:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0179e4516210.1371/journal.pone.0045162Novel effects of hormonal contraceptive use on the plasma proteome.Andrea R JosseBibiana Garcia-BailoKarina FischerAhmed El-SohemyHormonal contraceptive (HC) use may increase cardiometabolic risk; however, the effect of HC on emerging cardiometabolic and other disease risk factors is not clear.To determine the association between HC use and plasma proteins involved in established and emerging disease risk pathways.Concentrations of 54 high-abundance plasma proteins were measured simultaneously by LC-MRM/MS in 783 women from the Toronto Nutrigenomics and Health Study. C-reactive protein (CRP) was measured separately. ANCOVA was used to test differences in protein concentrations between users and non-users, and among HC users depending on total hormone dose. Linear regression was used to test the association between duration (years) of HC use and plasma protein concentrations. Principal components analysis (PCA) was used to identify plasma proteomic profiles in users and non-users.After Bonferroni correction, 19 proteins involved in inflammation, innate immunity, coagulation and blood pressure regulation were significantly different between users and non-users (P<0.0009). These differences were replicated across three distinct ethnocultural groups. Traditional markers of glucose and lipid metabolism were also significantly higher among HC users. Neither hormone dose nor duration of use affected protein concentrations. PCA identified 4 distinct proteomic profiles in users and 3 in non-users.HC use was associated with different concentrations of plasma proteins along various disease-related pathways, and these differences were present across different ethnicities. Aside from the known effect of HC on traditional biomarkers of cardiometabolic risk, HC use also affects numerous proteins that may be biomarkers of dysregulation in inflammation, coagulation and blood pressure.http://europepmc.org/articles/PMC3440362?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Andrea R Josse
Bibiana Garcia-Bailo
Karina Fischer
Ahmed El-Sohemy
spellingShingle Andrea R Josse
Bibiana Garcia-Bailo
Karina Fischer
Ahmed El-Sohemy
Novel effects of hormonal contraceptive use on the plasma proteome.
PLoS ONE
author_facet Andrea R Josse
Bibiana Garcia-Bailo
Karina Fischer
Ahmed El-Sohemy
author_sort Andrea R Josse
title Novel effects of hormonal contraceptive use on the plasma proteome.
title_short Novel effects of hormonal contraceptive use on the plasma proteome.
title_full Novel effects of hormonal contraceptive use on the plasma proteome.
title_fullStr Novel effects of hormonal contraceptive use on the plasma proteome.
title_full_unstemmed Novel effects of hormonal contraceptive use on the plasma proteome.
title_sort novel effects of hormonal contraceptive use on the plasma proteome.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Hormonal contraceptive (HC) use may increase cardiometabolic risk; however, the effect of HC on emerging cardiometabolic and other disease risk factors is not clear.To determine the association between HC use and plasma proteins involved in established and emerging disease risk pathways.Concentrations of 54 high-abundance plasma proteins were measured simultaneously by LC-MRM/MS in 783 women from the Toronto Nutrigenomics and Health Study. C-reactive protein (CRP) was measured separately. ANCOVA was used to test differences in protein concentrations between users and non-users, and among HC users depending on total hormone dose. Linear regression was used to test the association between duration (years) of HC use and plasma protein concentrations. Principal components analysis (PCA) was used to identify plasma proteomic profiles in users and non-users.After Bonferroni correction, 19 proteins involved in inflammation, innate immunity, coagulation and blood pressure regulation were significantly different between users and non-users (P<0.0009). These differences were replicated across three distinct ethnocultural groups. Traditional markers of glucose and lipid metabolism were also significantly higher among HC users. Neither hormone dose nor duration of use affected protein concentrations. PCA identified 4 distinct proteomic profiles in users and 3 in non-users.HC use was associated with different concentrations of plasma proteins along various disease-related pathways, and these differences were present across different ethnicities. Aside from the known effect of HC on traditional biomarkers of cardiometabolic risk, HC use also affects numerous proteins that may be biomarkers of dysregulation in inflammation, coagulation and blood pressure.
url http://europepmc.org/articles/PMC3440362?pdf=render
work_keys_str_mv AT andrearjosse noveleffectsofhormonalcontraceptiveuseontheplasmaproteome
AT bibianagarciabailo noveleffectsofhormonalcontraceptiveuseontheplasmaproteome
AT karinafischer noveleffectsofhormonalcontraceptiveuseontheplasmaproteome
AT ahmedelsohemy noveleffectsofhormonalcontraceptiveuseontheplasmaproteome
_version_ 1724787611097104384